| Donald G Moses, MD | |
|
2100 Highway 61 N, Vicksburg, MS 39183-8211 | |
| (601) 883-5000 | |
| Not Available |
| Full Name | Donald G Moses |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 37 Years |
| Location | 2100 Highway 61 N, Vicksburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740360221 | NPI | - | NPPES |
| 00122052 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | 16668 (Mississippi) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 16668 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lafayette General Medical Center | Lafayette, LA | Hospital |
| Acadia General Hospital | Crowley, LA | Hospital |
| Park Place Surgical Hospital | Lafayette, LA | Hospital |
| Lafayette Surgical Specialty Hospital | Lafayette, LA | Hospital |
| Abrom Kaplan Memorial Hospital | Kaplan, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Preferred Anatomic Pathology Services Inc | 8123922903 | 6 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
The Pap smear test is one of the easiest ways to screen young women for cervical cancer. Cervical cancer kills thousands of women and if detected early can be treated successfully. A new problem has arisen however with the smear test. Many young women are embarrassed about getting a Pap smear test routinely to screen against cervical cancer.
Virginia Tech released today the results of its 2013 adult football helmet ratings, designed to identify differences between the abilities of helmets to reduce the risk of concussion. A total of four helmets achieved a 5 star mark, which is the highest rating awarded by the Virginia Tech Helmet Ratings-.
› Verified 3 days ago
| Entity Name | Preferred Anatomic Pathology Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700873833 PECOS PAC ID: 8123922903 Enrollment ID: O20040323000293 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
The Pap smear test is one of the easiest ways to screen young women for cervical cancer. Cervical cancer kills thousands of women and if detected early can be treated successfully. A new problem has arisen however with the smear test. Many young women are embarrassed about getting a Pap smear test routinely to screen against cervical cancer.
Virginia Tech released today the results of its 2013 adult football helmet ratings, designed to identify differences between the abilities of helmets to reduce the risk of concussion. A total of four helmets achieved a 5 star mark, which is the highest rating awarded by the Virginia Tech Helmet Ratings-.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald G Moses, MD 2100 Highway 61 N, Vicksburg, MS 39183-8211 Ph: (601) 883-5000 | Donald G Moses, MD 2100 Highway 61 N, Vicksburg, MS 39183-8211 Ph: (601) 883-5000 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
The Pap smear test is one of the easiest ways to screen young women for cervical cancer. Cervical cancer kills thousands of women and if detected early can be treated successfully. A new problem has arisen however with the smear test. Many young women are embarrassed about getting a Pap smear test routinely to screen against cervical cancer.
Virginia Tech released today the results of its 2013 adult football helmet ratings, designed to identify differences between the abilities of helmets to reduce the risk of concussion. A total of four helmets achieved a 5 star mark, which is the highest rating awarded by the Virginia Tech Helmet Ratings-.
› Verified 3 days ago